This press release is an English translation of a Japanese-language press release. The official language of this press release is Japanese, and the Japanese version takes precedence over the English version in terms of content and interpretation.

<Press Release>
28th July 2026

Company:	Chordia Therapeutics Inc
Representative:	Chief Executive Officer Hiroshi Miyake
	(Security Code: 190A TSE Growth Market)
Contact:	Chief Financial Officer Masaru Okatani
MAIL :	info@chordiatherapeutics.com

Announcement Regarding the Review Status of Orphan Drug Designation for Rogocekib, a CLK Inhibitor

Chordia Therapeutics Inc (Head Office: Fujisawa City, Kanagawa Prefecture; CEO: Hiroshi Miyake, "Chordia") hereby announces that the Second Committee on Drugs of the Pharmaceutical Affairs Council of the Ministry of Health, Labour and Welfare (MHLW) held on July 27, 2026, endorsed the designation of rogocekib, Chordia's lead pipeline candidate and a CLK inhibitor, as an orphan drug for the treatment of relapsed or refractory acute myeloid leukemia (AML). Chordia will promptly announce the receipt of the orphan drug designation notification upon completion of the formal designation procedures by the MHLW.

There is no impact on business performance resulting from this designation.

About CLK inhibitor rogocekib (development code: CTX-712)

rogocekib is a first-in-class, selective, orally available small molecule inhibitor targeting CDC2-like kinase (CLK), a key regulator of RNA splicing involved in cell proliferation. It has received Orphan Drug Designation (ODD) from the FDA for the treatment of AML and is currently undergoing a Phase 1/2 clinical trial in the United States.

About Chordia Therapeutics

Chordia Therapeutics is a research and development-stage biopharmaceutical company specializing in oncology with clinical-stage assets, headquartered in Fujisawa City, Kanagawa Prefecture. Chordia's lead asset, rogocekib (CLK inhibitor CTX-712), is under Phase 1/2 clinical study in the US. Rogocekib potentially targets the vulnerability of cancer and is expected to deliver benefits to patients of various types of cancer. In addition to rogocekib, Chordia is engaged in the research and development of several assets, including ocipumaltib (MALT1 inhibitor CTX-177) , CTX-439, a CDK12 inhibitor, and GCN2 inhibitors. For more information, please visit our website https://www.chordiatherapeutics.com/en/.